Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeiGene's PD-1 Recommended for Approval by China's CDE

publication date: Nov 14, 2019

BeiGene's PD-1 candidate tislelizumab was recommended for approval by China’s Center for Drug Evaluation as a treatment for classical Hodgkin’s lymphoma. The PD-1 candidate is the first BeiGene drug to advance this far and would be the sixth PD-1/PD-L1 to be launched in China. The CDE performed a technical review with a recommendation to approve the immunotherapy and sent tislelizumab to China's National Medical Products Administration for final approval, which BeiGene, a Beijing biopharma, expects before the end of 2019. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here